Literature DB >> 15187889

Genetics of chondrosarcoma and related tumors.

Avery A Sandberg1.   

Abstract

PURPOSE OF REVIEW: The burgeoning body of information on the genetic changes present in and underlying the development and biology of human cancers has carried implications regarding the possible genetic events that are responsible for not only the genesis of these cancers but also the hope of the cure for these cancers. Chondrosarcomas are a group of tumors that fall into this category. The purpose of this review is to summarize the genetic findings in these tumors. RECENT
FINDINGS: The histopathologic variability of chondrosarcomas is reflected in the complexity and lack of specificity of their cytogenetic and molecular genetic findings, except for extraskeletal myxoid chondrosarcomas. These are characterized in the preponderant number of cases by a translocation, t(9;22)(q22;q12), and in a small number of cases by variant translocations t(9;17)(q22;q11) and t(9;15)(q22;q21). These translocations lead to the formation of abnormal fusion genes and gene products (proteins). In each of these translocations, the CHN gene is involved, resulting in the chimeric fusion genes EWS/CHN, RBP56/CHN, and TCF12/CHN, respectively. The specific translocations and their associated molecular genetic changes are diagnostic of extraskeletal myxoid chondrosarcomas. The abnormal proteins resulting from these fusion genes aberrantly affect gene transcription and cellular signaling pathways thought to be responsible for initiating sarcoma formation. In skeletal (central) chondrosarcomas of varying histopathologic types, the cytogenetic and molecular genetic findings are variable, complex, and apparently lacking in specificity. These changes may reflect a stepwise process (or processes) of oncogenesis involving an array of genes.
SUMMARY: Although some cartilaginous tumors are characterized by specific or recurrent chromosome alterations and molecular genetic changes, much is yet to be learned about the nature and sequence of these genetics events and about their unique role in the stepwise process involved in the development and biology of each tumor type, both malignant and nonmalignant. Until such time, some of the genetic changes, particularly the presence of specific translocations, can be of definite diagnostic value.

Entities:  

Mesh:

Year:  2004        PMID: 15187889     DOI: 10.1097/01.cco.0000129678.72521.e5

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  14 in total

Review 1.  An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.

Authors:  Mojdeh Safari; Alireza Khoshnevisan
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

2.  The Investigation of ADAMTS16 in Insulin-Induced Human Chondrosarcoma Cells.

Authors:  Ozlem Cakmak; Ismail Comertoglu; Ridvan Firat; Haci Kemal Erdemli; S Fatih Kursunlu; Sumeyya Akyol; Veli Ugurcu; Aynur Altuntas; Bahattin Adam; Kadir Demircan
Journal:  Cancer Biother Radiopharm       Date:  2015-08       Impact factor: 3.099

Review 3.  Molecular pathology of chondroid neoplasms: part 2, malignant lesions.

Authors:  W C Bell; M J Klein; M J Pitt; G P Siegal
Journal:  Skeletal Radiol       Date:  2006-10-18       Impact factor: 2.199

4.  In malignant cartilagenous tumors, immunohistochemical expression of procollagen PC1CP peptide is higher and that of PC2CP lower than in benign cartilaginous lesions.

Authors:  Camille Delaunay-Lemarie; Jean-Baptiste Vincourt; Béatrice Marie; Shyue-Fang Battaglia-Hsu; Stéphanie Etienne; François Sirveaux; Phi Linh Nguyen Thi; Jacques Magdalou; Jean-Michel Vignaud; Guillaume Gauchotte
Journal:  Virchows Arch       Date:  2015-06-23       Impact factor: 4.064

Review 5.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

6.  Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy.

Authors:  Alex D Drilon; Sanjay Popat; Gauri Bhuchar; David R D'Adamo; Mary Louise Keohan; Cyril Fisher; Cristina R Antonescu; Samuel Singer; Murray F Brennan; Ian Judson; Robert G Maki
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

7.  Chondrosarcoma apoplexy in thoracic spine.

Authors:  Sang Woo Kim; Min Su Kim; Young Jin Jung
Journal:  J Korean Neurosurg Soc       Date:  2013-01-31

8.  PTHR1 mutations associated with Ollier disease result in receptor loss of function.

Authors:  Alain Couvineau; Vinciane Wouters; Guylène Bertrand; Christiane Rouyer; Bénédicte Gérard; Laurence M Boon; Bernard Grandchamp; Miikka Vikkula; Caroline Silve
Journal:  Hum Mol Genet       Date:  2008-06-17       Impact factor: 6.150

9.  rAAV Vectors as Safe and Efficient Tools for the Stable Delivery of Genes to Primary Human Chondrosarcoma Cells In Vitro and In Situ.

Authors:  Henning Madry; Jagadeesh K Venkatesan; Gertrud Schmitt; Sarah Schetting; Myriam Ekici; Dieter Kohn; Magali Cucchiarini
Journal:  Sarcoma       Date:  2012-05-07

10.  Temporal Chondroblastoma with a Novel Chromosomal Translocation (2;5) (q33;q13).

Authors:  Andrew P Carlson; Howard Yonas; Garth T Olson; Kaaren K Reichard; Rafael Medina-Flores
Journal:  Skull Base Rep       Date:  2011-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.